Our relentless dedication to accuracy, timeliness and regulatory rigor enables your therapeutic innovations to reach patients faster.
Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Biomarkers
Immunogenicity
Pharmacokinetics & Pharmacodynamics (PK/PD)
Cell-Based Assays
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for therapeutics innovation.
Biosimilars
Gene Therapy
Antibody Drug Conjugates (ADCs)
Immuno-oncology
Cell therapies are emerging and evolving as promising therapies for a variety of disease indications. The ability to detect anti-drug antibodies (ADA) is important for patients receiving cell-based therapies. However, approaches to detecting ADAs against cell-surface biotherapeutics vary utilizing either traditional ligand binding assays or cell-based binding assays. Both ADA assay approaches have been utilized but there is no current regulatory guidance on which format is more appropriate for these therapeutics. In this presentation, we will discuss the challenges of both approaches and current industry practices.
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
June 23, 2022What Parameters Are Acquired from a PK Study?
June 23, 2022BioAgilytix appoints Christie Knittel Mabry as new Chief People Officer
June 16, 2022BioAgilytix Appoints Euan Menzies as Chairman and Chief Executive Officer
August 6, 2020Analytical Assays Determine Biosimilar Product Quality
December 2, 2019Immunogenicity Assessment of Gene Therapy Compounds
Platforms
Services
